National reimbursement decision for Optune® in Germany anticipated in 2020 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure’s EF-14 phase 3 pivotal trial, patients with newly diagnosed glioblastoma (GBM) lived …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle’s presentation will begin at 9 a.m. EDT and will be followed by a Q&A session. Mr. Doyle will also participate in …

NovoTTF-100L, a Tumor Treating Fields delivery system, is the first FDA-approved mesothelioma treatment in more than 15 years In the STELLAR trial, malignant pleural mesothelioma patients treated with Tumor Treating Fields plus platinum-based chemotherapy experienced a median overall survival of 18.2 months ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the U.S. Food …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Proposed LCDs are subject to a 45-day public comment period during which the DME …

Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018 Mesothelioma humanitarian device exemption application under FDA review Enrollment ongoing in four phase 3 pivotal trials, creating a significant market expansion opportunity in some of the most aggressive forms of cancer …

The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating Fields dosimetry and treatment planning The International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, is the official journal of the American Society for Radiation Oncology ST. HELIER, Jersey–(BUSINESS …

Novocure’s mission and values support its overarching patient-forward vision to make a difference in cancer ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highlights and selected financial information. In 2018, Novocure made a commitment to put …

ST. HELIER, Jersey–(BUSINESS WIRE)– The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta. The grants represent a joint effort between Novocure (NASDAQ: NVCR) and the AACR to promote and support innovative research on Tumor Treating Fields. …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2019, at 8 a.m. …

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer Ovarian cancer is the fifth leading cause of cancer death among women ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor …